# Polar Capital Future Healthcare

a sub-fund of Premium Selection UCITS ICAV Class K - acc - USD, ISIN IE00BNGJL640 March 2024 Factsheet

This document is marketing material. Unless otherwise stated all data as at 31/03/2024. Investors should read the Key Investor Information Document and Prospectus prior to investing.

#### **FUND OVERVIEW**


The Fund aims to preserve capital and achieve long term capital appreciation, by investing in a globally diversified portfolio of companies within the healthcare sector. The Fund invests directly or indirectly up to 100% of its Net Asset Value (and typically at least two thirds of its Net Asset Value) in equities and equity related securities of healthcare companies worldwide, which may be listed on a Regulated Market or unlisted. The Fund may invest up to 10% of its Net Asset Value in global listed securities other than healthcare related companies and up to 30% of its Net Asset Value in ancillary liquid assets and cash. The total amount of these investments is limited to a third of the Fund's Net Asset Value. Up to 30% of the Net Asset Value may be invested in emerging markets. The Fund may invest up to 20% of its Net Asset Value in equity warrants, up 20% of its Net Asset Value in Depositary Receipts (including ADRs, EDRs and/or GDRs) and up to 10% of its Net Asset Value in participatory notes. The Fund can invest directly or indirectly up to 20% of its Net Asset Value in China A shares via both, the Shanghai-Hong Kong Stock Connect or the Shenzhen-Hong Kong Stock Connect and China H-shares traded on the Hong Kong Stock Exchange. The Fund may use investment techniques known as 'hedging' to provide protection against exchange risks for the efficient management of its investments or to hedge a non-base currency share class. Such techniques may include options, forwards, futures, swaps and securities lending agreements. The Fund may be leveraged up to 100% of the Fund's NAV. The Fund may invest up to 10% of its Net Asset Value in other collective investment schemes.

#### **FUND OPPORTUNITIES**

A highly qualified and experienced investment manager actively manages the Fund. Equities are selected using a stock selection process to generate a high conviction portfolio participating in specific themes, which are identified as the future of healthcare, namely, future medicines and technologies, new markets, healthcare delivery, prevention and outsourcing.

#### **RISK FACTORS**

A significant portion of the Fund's assets may be invested in emerging market assets. Emerging markets generally carry greater political, legal, counterparty and operational risk. In exceptional circumstances the Fund may encounter difficulties when buying and selling these investments. Due to the fact that the Fund may invest into the China A Shares market via both, Shanghai-Hong Kong Stock Connect and/or Shenzhen-Hong Kong Stock Connect, various additional risks which include but are not limited to regulatory risks and suspension risks may thereby be caused and should be emphasised to the general investment and equity related risks.



Source: Three Rock Capital Management Ltd., MSCI. The Fund was established in April 2021. This Class was created in April 2021. Share Class and Benchmark performance displayed in USD. Performance is shown on a Net Asset Value (NAV) basis, with gross income reinvested.

Past performance is not necessarily indicative of future performance and should not be the sole factor of consideration when selecting a product.

All financial investments involve an element of risk. Therefore, the value of your investment and the income from it will vary and your initial investment amount cannot be guaranteed



#### **RISK AND REWARD PROFILE**

Lower F	Risk				High	er Risk	
Typically Lower Rewards Typically Higher Rewards							
1	2	3	4	5	6	7	
KEY FACTS			IE00BN	GJL64	0		
Valoren			59202615				
Management Company			Three Rock Capital				
Investment Manager			Management Ltd. Polar Capital LLP				
Asset Class			Equity				
Share Class Currency			USD				
Base Currency			USD				
Benchmark			MSCI AC World Daily Total Return Net Health Care USD Index				
Fund Inception Date			09/04/2021				
Share Class Launch Date			09/04/2021				
Domicile			Ireland				
Fund Type			UCITS				
	Minimum Initial Investment			USD 1,000,000			
Settlement			Trade Date + 2 BD				
Dealing Frequency			Daily				
Distribution			None				
Total Fund Assets			USD 141.62 m				
Total Shar Assets	Total Share Class Assets			USD 17.12 m			
FEES A	ND (	CHAP	RGES				
Ongoing charges			1.00%				
Entry char	Entry charge			Max 5.00%			
Exit charge			Max 3.00%				
TER			1.00%				
Performance fees			0.00%				

### TOP 10 HOLDINGS (%)

ELI LILLY & CO	8.15
ZEALAND PHARMA A/S	8.00
SWEDISH ORPHAN BIOVITRUM AB	7.20
INTUITIVE SURGICAL INC	5.39
JOHNSON & JOHNSON	5.34
HCA HEALTHCARE INC	5.20
MAX HEALTHCARE INSTITUTE LTD	4.80
ACADIA HEALTHCARE CO INC	3.84
CHEMED CORP	3.72
XENON PHARMACEUTICALS INC	3.69
Total of Portfolio	55.33

#### CURRENCY EXPOSURE (%)

UNITED STATES DOLLAR	56.53
DANISH KRONE	8.02
SWEDISH KRONA	7.21
JAPANESE YEN	6.70
EURO	6.36
INDIAN RUPEE	4.81
HONG KONG DOLLAR	3.17
UNITED KINGDOM POUND STERLING	3.05
HUNGARIAN FORINT	2.49
SWISS FRANC	1.66
Total of Portfolio	100.00


30%

40%

50%

60%

### **SECTOR EXPOSURE**



Source: Three Rock Capital Management Ltd. All data shown is subject to change.

#### GLOSSARY

#### Business Day (BD): any bank working day in Ireland.

Benchmark (BM): an index that can be used by an investment fund as the basis of comparison for assessing the performance achieved.

Ongoing Charges: is a figure representing all annual charges and other payments taken from the fund.

SRRI: is value based on the volatility of the fund, which gives an indication of the overall risk and reward profile of the Fund.

## **IMPORTANT LEGAL INFORMATION**

Source: Three Rock Capital Management Ltd. (TRCM), unless otherwise stated. Where applicable and, unless otherwise noted, performance is shown net of fees, on a NAV to NAV basis, gross of taxes. TRCM has not independently verified the information from other sources and TRCM gives no assurance, expressed or implied, as to whether such information is accurate, true or complete. All data and information provided is updated at the date of this Document, unless otherwise indicated. All financial investments involve an element of risk. Therefore, the value of your investment and the income from it will vary and your initial investment amount cannot be guaranteed. Premium Selection UCITS ICAV (PSI) is an open-ended investment company established in Ireland which is available for sale in certain jurisdictions only. PSI is not available for sale in the U.S. or to U.S. persons. Product information concerning PSI may not be published in the U.S. Subscriptions in any sub-fund of the PSI are valid only if made on the basis of the current Prospectus and respective Supplement, the most recent financial reports and the Key Investor Information Document (KIID), which are available on www.fundinfo.com. Prospectuses, Key Investor Information Documents and application forms may not be available to investors in certain jurisdictions where the Fund in question has not be reproduced or relist. This material is produced by PSI with the greatest of care and to the best of its knowledge and belief. Data and information may not be exproved the in residuent, which such distribution, publication, making available or use is contrary to law or other regulations. Nothing contained herein constitutes investment, legal, tax or other advice, nor is it to be solely relied on in making an investment or other decision. This document qualifies as marketing material. The views expressed herein are those of the manager at the time and are subject to change. The price of shares may go down as well as up and the price will depend on fluctuations in fina

Group AG, with registered office at 0.1 momas Street Dublin 8, ireland. A summary of investor rights and details for local language investor redress arrangements can be found at www.threerockcapital.com/cbdr. Source: MSCI. Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in or related to compiling, computing or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI's express written consent.

SWITZERLAND: 1741 Fund Solutions AG, Burggraben 16, CH-9000 St. Gallen, is the Swiss Representative and Tellco AG, Bahnhofstrasse 4, Postfach 713, CH-6431 Schwyz, the Swiss Paying Agent. The Prospectus, Key Investor Information Document, the Instrument of Incorporation, the latest and any previous annual and semi-annual reports, in German as applicable, are available free of charge from the Swiss representative. GERMANY: The legal documents in English and the KIID in German can be obtained free of charge, from the Information Agent GerFIS – German Fund Information Service UG (Haftungsbeschränkt) Zum Eichhagen 4, 21382 Brietlingen, Germany or on the internet at www.fundinfo.com. AUSTRIA: The legal documents in English and the KIID in German can be obtained free of charge, from the Paying and Information Agent in Austria, Erste Bank der oesterreichischen Sparkassen AG, Am

## **COUNTRY EXPOSURE**



Belvedere 1, 1100 Vienna, Austria or on the internet at www.fundinfo.com. FRANCE: The prospectus, the annual report and the most recent half-yearly report in English and the KIID in French can be obtained free of charge from the centralising agent in France Société Générale, 29, Boulevard Haussmann 7500 Paris OR on the internet at www.fundinfo.com. The prospectus is not available in French. LUXEMBOURG: The legal documents in English can be obtained free of charge on the internet at www.fundinfo.com. BGT BN: The English version of the prospectus and the English version of the KID can be obtained free of charge on the internet at www.fundinfo.com. BGT BN: The English version of the prospectus and the English version of the KID can be obtained at www.fundinfo.com. This advertisement or publication has not been reviewed by the Monestary Authority of Singapore. For distribution share classes, dividends are not guaranteed and may be paid out of capital. Dividend data may not be available on the assumption that all distributions are classes, dividends are not guaranteed and may be paid out of capital. Dividend data may not be available on the assumption that all distributions are classes, dividends result in a reduction of the NAV per share of the Fund on the ex-dividend date. Actual dividend payout will be subject to the manager's discretion. Fund performance is shown on a NAV to NAV basis on the assumption that all distributions are tervices (LK Aking into acccuru all charges which would have been payable upon such reinvestmet. SPANI: The legal documents in English and the KIID in Spanish can be obtained free of charge from the representative in Span, Allfunds Bank S.A.U.C. / Padres Dominicos 7, 28050 Madrid, Spain or on the internet at www.fundinfo.com. The advected with the CHNV under 1944. UK: As far as UCTS domicided in English, pree of charge, from the Facilities documents in a services (LK UL) and address is 2nd Flore. 100 CC (V AND, United Kingdownor on the internet at www.fundinfo.com. The sadvected with the